MedTrace Logo

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

NCT00511992 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

Conditions

Interventions

DRUG

Avastin

Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2) Consolidation Treatment: Avastin 15mg/kg IV every 21 days x 12 cycles

DRUG

Paclitaxel

Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles

DRUG

Cisplatin

75mg/m2 IP day 2 every 21 days x 6 cycles

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • D. Scott McMeekin, MD · University of Oklahoma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2015-08-03
Completion
2015-08-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511992 on ClinicalTrials.gov